LY9 Antikörper (AA 160-360)

Produktnummer ABIN7171457

Produktdetails anti-LY9 Antikörper

Target: LY9 (CD229) (Lymphocyte Antigen 9 (CD229))

Bindungsspezifität: AA 160-360

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LY9 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), ELISA

Kreuzreaktivität: Human

Aufreinigung: Antigen Affinity Purified

Immunogen: Recombinant Human T-lymphocyte surface antigen Ly-9 protein (160-360AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu LY9

Target: LY9 (CD229) (Lymphocyte Antigen 9 (CD229))

Andere Bezeichnung: LY9 (CD229 Produkte)

Synonyme: LY9 antikoerper, CD229 antikoerper, SLAMF3 antikoerper, hly9 antikoerper, mLY9 antikoerper, AI893573 antikoerper, Lgp100 antikoerper, Ly-9 antikoerper, T100 antikoerper, lymphocyte antigen 9 antikoerper, LY9 antikoerper, Ly9 antikoerper

Hintergrund:

Background: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion, the costimulatory activity requires SH2D1A (PubMed:22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells (By similarity).

Aliases: CD229 antibody, Cell surface molecule Ly-9 antibody, Cell surface molecule Ly9 antibody, hly9 antibody, LY 9 antibody, Ly9 antibody, LY9_HUMAN antibody, Lymphocyte antigen 9 antibody, mLY9 antibody, Signaling lymphocytic activation molecule 3 antibody, SLAM family member 3 antibody, SLAMF3 antibody, T lymphocyte surface antigen Ly9 precursor antibody, T-lymphocyte surface antigen Ly-9 antibody

UniProt: Q9HBG7

Pathways: BCR Signaling